Blockade of colony stimulating factor-1 (CSF-1) leads to inhibition of DSS-induced colitis

Inflammatory Bowel Diseases

Volumn 13, Issue 2, 2007, Pages 219-224

  Marshall, Diane ^a   Cameron, James ^a   Lightwood, Daniel ^a   Lawson, Alastair D G ^a  

^a UCB PHARMA   (Belgium)

Author keywords

Antibody; CSF 1; Experimental colitis; Macrophage

Indexed keywords

101 4 ANTIBODY; AB 33 ANTIBODY; COLONY STIMULATING FACTOR 1; CYTOKINE ANTIBODY; DEXTRAN SULFATE; DRINKING WATER; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG INHIBITION; ENTERITIS; INTESTINE MUCOSA; LYMPHOCYTIC INFILTRATION; MACROPHAGE MIGRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL MOVEMENT; COLITIS; COLON; CYTOKINES; DEXTRAN SULFATE; MACROPHAGE COLONY-STIMULATING FACTOR; MALE; MICE; MICE, INBRED BALB C;

EID: 34249328414     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20055     Document Type: Article

References (31)

1. Mahida YR, Patel S, Wu K, et al. Interleukin 2 receptor expression by macrophages in inflammatory bowel disease. Clin Exp Immunol. 1988; 74:382-386.
2. Mahida YR, Wu KC, Jewell DP. Respiratory burst activity of intestinal macrophages in normal and inflammatory bowel disease. Gut. 1988;30: 1362-1370.
3. Rugtveit J, Brandtzaeg P, Halstensen TS, et al. Increased macrophage subset in inflammatory bowel disease: apparent recruitment from peripheral blood monocytes. Gut. 1994;35:669-674.
4. Rugtveit J, Haraldsen G, Hogasen AK, et al. Respiratory burst of intestinal macrophages in inflammatory bowel disease is mainly caused by CD14+L1+monocyte derived cells. Gut. 1995;37:367-373.
5. Reinecker HC, Steffen M, Witthoeft T, et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol. 1993;94:174-181.
6. McAlindon M, Mahida YR. Cytokines and the gut. Eur J Gastroenterol Hepatol. 1997;9:1045-1050.
7. op) phenotype with a CSF-1 transgene and identification of sites of local CSF-1 synthesis. Blood. 2001;98:74-84.
8. op mice by transgenic expression of cell surface CSF-1. Blood. 2004;103: 1114-1123.
9. Nandi M, Akhter MP, Seifert MF, et al. Developmental and functional significance of the CSF-1 proteoglycan chondroitin sulfate chain. Blood. 2006;107:786-795.
10. Roth P, Stanley ER. The biology of CSF-1 and its receptor. Curr Top Microbiol Immunol. 1992;181:141-167.
11. Chitu V, Stanley ER. Colony-stimulating factor-1 in immunity and inflammation. Curr Opin Immunol. 2005;17:1-10.
12. Klebl FH, Olsen JE, Jain S, et al. Expression of macrophage-colony stimulating factor in normal and inflammatory bowel disease intestine. J Pathol. 2001;195:609-615.
13. Wiktor-Jedrzejczak W, Ansari AA, Szperl M, et al. Distinct in vivo functions of two macrophage subpopulations as evidenced by studies using macrophage-deficient op/op mouse. Eur J Immunol. 1992;22: 1951-1954.
14. Okayasu I, Hatakeyama S, Yamada M, et al. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology. 1990;98:694-702.
15. Babcook JS, Leslie KB, Olsen OA, et al. A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities. Proc Natl Acad Sci USA. 1996;93: 7843-7848.
16. Metcalf D. Studies on colony formation in vitro by mouse bone marrow cells. II. Action of colony stimulating factor. J Cell Physiol. 1970;76: 89-99.
17. Dieleman LA, Palmen MJ, Akol H, et al. Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterised by Th1 and Th2 cytokines. Clin Exp Immunol. 1998;114:385-391.
18. Borjesson L, Aldenborg F, Delbro DS. Functional effects of dextran sulphate sodium (DSS) treatment on the longitudinal muscle of rat distal colon. J Auton Pharmacol. 2001;21:121-129.
19. Dieleman LA, Ridwan BU, Tennyson GS, et al. Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology. 1994;107:1643-1652.
20. Ni J, Chen SF, Hollander D. Effects of dextran sulphate sodium on intestinal epithelial cells and intestinal lymphocytes. Gut. 1996;39:234-241.
21. Wiktor-Jedrzejczak W, Bartocci A, Ferrante AW Jr, et al. Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse. Proc Natl Acad Sci USA. 1990;87:4828-4832.
22. Lin EY, Nguyen AV, Russel RG, et al. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med. 2001;193:727-740.
23. Lenda DM, Kikawada E, Stanley ER, et al. Reduced macrophage recruitment, proliferation, and activation in colony-stimulating factor-1-deficient mice results in decreased tubular apoptosis during renal inflammation. J Immunol. 2003;170:3254-3262.
24. pr mice. J Immunol. 2004;173:4744-4754.
25. Campbell IK, Rich MJ, Bischof RJ, et al. The colony-stimulating factors and collagen-induced arthritis: exacerbation of disease by M-CSF and G-CSF and requirement for endogenous M-CSF. J Leuk Biol. 2000;68: 144-150.
26. Egger B, Bajaj-Elliott M, MacDonald TT, et al. Characterisation of acute murine dextran sodium sulphate colitis: cytokine profile and dose dependency. Digestion. 2000;62:240-248.
27. Krieglstein CF, Cerwinka WH, Sprague AG, et al. Collagen-binding integrin α1β1 regulates intestinal inflammation in experimental colitis. J Clin Invest. 2002;110:1773-1782.
28. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology. 1998;115:182-205.
29. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumour necrosis factor α for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997;337:1029-1035.
30. Schreiber S, Khaliq-Kareemi M, Lawrence I, et al. Certolizumab pegol, a humanised anti-TNF PEGylated Fab fragment, is safe and effective in the maintenance of response and remission following induction in active Crohn's disease: a Phase III study (PRECiSE). In Thirteenth United European Gastroenterology Week, Copenhagen, Denmark, October 15-19, 2005.
31. Ito H, Takazoe M, Fukuda Y, et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology. 2004;126:989-996.